The article title reports that distinct monocyte phenotypes are associated with peri‑coronary inflammation in persons with and without HIV who do not have diagnosed cardiovascular disease. That is the only substantive content present in the supplied source. The full article text, including the abstract, methods, results, tables, figures and author list, was not included in the provided material. As a result, no direct data, numerical outcomes, or methodological descriptions could be extracted from the source content delivered for this rewrite.
The absence of primary text means the following cannot be verified here: who performed the study, how many participants were enrolled, what imaging or laboratory assays were used, and what statistical approaches shaped the reported associations. Readers must access the full Frontiers in Immunology article to review those elements.
The supplied content did not include any participant-level information. The title suggests the cohort included persons both with and without HIV and that participants lacked clinical cardiovascular disease. Beyond that implication, no concrete sample sizes, age ranges, sex distribution, antiretroviral therapy status, viral suppression rates, cardiovascular risk factor profiles, or other inclusion/exclusion criteria were provided. The source did not report whether the analysis was cross‑sectional or longitudinal, nor whether subgroups (for example by sex or smoking status) were prespecified.
Without these cohort details, assessment of the internal and external validity of the reported association is not possible from the supplied text. Investigators reported a relationship in the title, but the strength and scope of that relationship cannot be appraised here.
The title connects monocyte phenotypes to peri‑coronary inflammation, implying use of both immunophenotyping and vascular imaging. However, the provided material did not describe any laboratory methods such as flow cytometry panels, gating strategies, or marker definitions for the monocyte subsets referenced. The specific markers that defined the “distinct” phenotypes were not included.
Equally opaque are the imaging methods. The title refers to peri‑coronary inflammation, but the text did not state whether inflammation was assessed by coronary computed tomography angiography (CTA) with perivascular fat attenuation index, PET imaging with FDG uptake, MRI, or another modality. The operational definition of peri‑coronary inflammation and any quantitative thresholds used were not reported in the supplied content. The source also did not provide primary or secondary endpoints, follow‑up duration, or whether clinical cardiovascular events were captured beyond the study’s imaging assessment.
The title implies a biologic link between innate immune cell heterogeneity and localized coronary inflammation in people both with and without HIV. If substantiated in the full article, that observation could inform mechanistic models of HIV‑associated cardiovascular risk and identify candidate biomarkers for subclinical vascular inflammation. Still, the provided source did not include the data needed to evaluate any of these possibilities.
Key unanswered questions left by the missing text include:
Clinicians and researchers should therefore treat the title as a prompt to read the full article for the methods and results needed to judge clinical relevance.
Because the supplied material omitted the core manuscript, the principal limitation of this rewrite is absence of verifiable data. The source did not provide methods, results, or author attributions; no claims beyond the published title can be cited here. This gap prevents evaluation of bias, reproducibility, and applicability.
To permit critical appraisal and clinical use, the full article must report at minimum: detailed cohort characteristics; clear definitions of the monocyte phenotypes and the laboratory assays used; imaging modality and quantitative criteria for peri‑coronary inflammation; statistical models and covariates; and effect estimates with confidence intervals or p‑values. Without those elements, specific clinical or translational recommendations cannot be responsibly drawn from the material provided.
Next steps for readers: consult the complete Frontiers in Immunology paper for the primary data, or contact the corresponding author listed in the published article for clarifications. Specific unanswered clinical questions remain—documented here as missing in the provided source text—such as which monocyte markers track most closely with coronary inflammation and whether these markers improve risk stratification above established predictors. The supply did not report regulatory milestones or planned trials; such information must be obtained from the full manuscript or subsequent communications from the authors.